Biointron established a single-B cell antibody discovery platform based on microfluidic technology. Combined with our proprietary fast antibody expression platform, it has been proven to be fast and efficient in many projects. This case study uses our high-speed single B cell sorting platform to`screen for PD-1 antibodies. Since our platform retains hundreds of sequences, we selected 62 hits to carry out further antibody expression and validation. From an ELISA binding assay, we see that most hits had excellent binding against PD-1, with 59 out of 62 antibodies showing positive binding against PD-1. In addition, most of the antibodies demonstrated high-affinity binding in the low nanomolar range (10-9). The project objective was to obtain specific antibodies against PD-1 at different epitopes.
Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, cells are selected and screened to identify clones that stably express the protein of interest at desired levels. This case study illustrates the successful generation of a tag-free vaccine protein.
Biointron has developed our own CHOK1-Fut8KO expression platform for afucosylated antibodies.
Biointron has developed a successful method for discovering alpaca VHH for over 200 projects, using flexible immunization strategies and a robust phage display screening platform.
ScientistとScience Exchangeとのご利用可能です。
